CRISPR Therapeutics AG has risen higher in 3 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 75 %. FUV This product is for educational purposes only. While there’s a lot to be optimistic about when it comes to CRISPR Therapeutics stock, there’s also enough to give investors some pause as well, mainly the possibility that its flagship CTX001 treatment will fail. CRISPR Therapeutics AG Common Shares (CRSP) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. On its last earning announcement, the company reported a profit of 0.95$ per share. Trending Stocks: ... the average rating for CRSP stock is "Buy." CSU, Used by many of the world's smartest investors, Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days, Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock with the most powerful seasonal trend this week, For Dividend Stocks, Blue Chip Stocks, Most Active Stocks, Most Shorted Stocks, Cheap Stocks, Stocks on Sale, and much more, Get new stock ideas every day delivered to your inbox based on income, stock ratings, seasonal trends, best value, and more, Gain full access to our most highly screened value stocks that even Buffett may approve. CRISPR Therapeutics is selling at 165.70 as of the 31st of January 2021; that is -1.03 percent down since the beginning of the trading day. Add CRSP to your portfolio and optimize it! Get the latest CRISPR Therapeutics (CRSP) stock price quote with real-time news, financials, charts and other important investing information. CRISPR Therapeutics AG Stock Price Forecast, "CRSP" Predictons for2021 While our free users beat the market by 7% per quarter, last quarter, our premium users have beaten the market by 22%. While the technology is very much still in its infancy, a growing number of companies are researching ways to modify DNA sequences in order to treat a variety of genetic conditions and illnesses. During that period the price should oscillate See CRISPR Therapeutics AG (CRSP) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The high price target for CRSP is $210.00 and the low price target for CRSP is $31.00. Their forecasts range from $21.00 to $72.50. CRISPR Stock Forecast: Genome editing has passed from science fiction to science fact. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. If you had invested in CRISPR Therapeutics AG stock at $14.09, your return over the last 4 years would have been 1,075.87%, for an annualized return of 85.18%. See: Characteristics and Risks of Standardized Options. APPS between -16.76% and +21.47%. Each premium signal is sent to all our premium users by mail. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. The 12-month stock price forecast is 146.56, which is a decrease of -10.91% from the latest price. The content on any of Financhill websites, products or communication is for educational purposes only. Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for, CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day, Arlington Financial Advisors LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP), Nia Impact Advisors LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP), CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer. © AIStockFinder 2018. Our research is based on sources that we believe to be reliable. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Get the latest CRISPR Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including CRISPR investment advice, charts, stats and more. The average price target is $155.20 with a high forecast of $210.00 and a low forecast of $45.00. Close price at the end of the last trading day (Tuesday, 26th Jan 2021) of the CRSP … Subscribe today to receive the latest AIStockFinder news via email. stock was originally listed at a price of $14.09 in Oct 19, 2016. Actual results may differ. Their average twelve-month price target is $141.79, predicting that the stock has a possible downside of 15.80%. Get the latest Crispr Therapeutics earnings report, revenues as well as upcoming CRSP earnings dates, historical financial reports, news, analysis & more. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 2.36, and its average true range (ATR) is 14.46. 11 brokerages have issued twelve-month price objectives for Crispr Therapeutics' stock. Get CRISPR Therapeutics AG (CRSP:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Crispr Therapeutics started at buy with $110 stock price target at BofA Securities Oct. 5, 2020 at 11:33 a.m. During that period the price should oscillate between … The stock's last reported lowest price was 160.37. In other news, VP Tony W. Ho sold 23,551 shares of the business’s stock in a transaction on Monday, December 21st. AIStockFinder is a company specialized in predictive algorithms. Prices shown are actual historical values and are not adjusted for either splits or dividends. Our first-in-class customer support provides our clients with timely responses to any trouble they might encounter. CRISPR's stock more than doubled last year while Editas' gained a respectable 27%. According to analyst projections, CRSP’s forecast low is $45 with $210 as the target high. Any opinions, news, research, analyses, prices, or other information offered by AIStockFinder is provided as general market commentary, and does not constitute investment advice. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. AIStockFinder will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on such information. Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 97.8 % based on the past 4 years of stock performance. Past performance is not a guarantee of future results, and a loss of original capital may occur. CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? Based on 13 analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. Dec. 4, 2017 Price forecast | 2 weeks: -0.46% | 1 month: -0.14% | 3 months: -0.73%. WMS No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. The Financhill.com educational training program and software services are provided to improve financial understanding. Secure Your Limited Time Only Trial Access, Characteristics and Risks of Standardized Options. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. The Investor Relations website contains information about CRISPR Therapeutics's business for stockholders, potential investors, and financial analysts. CRISPR Therapeutics Stock Forecast. None of the information presented should be construed as an offer to sell or buy any particular security. The company’s stock has been forecasted to trade at an average price of $146.56 over the course of the next 52 weeks, with a low of $45 and a high of $210. Unlike free users, our premium users receive all forecasts, without any delay. Investing involves substantial risk. In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. I confirm my subscription to AIStockFinder's newsletter. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. CRISPR Therapeutics AG (CRSP) projections and forecasts Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. The biotech plans to begin an early-stage clinical study … On average, they anticipate Crispr Therapeutics' stock price to reach $48.9167 in the next twelve months. On average, 9 Wall Street analysts forecast CRSP's earnings for 2020 to be $-289,223,931, with the lowest CRSP earnings forecast at $-305,698,712, and the highest CRSP earnings forecast at $-252,613,307. Nothing here in constitutes a recommendation respecting the particular security illustrated. Disclaimer: Past performance is no guarantee of future performance. CRISPR Therapeutics AG Stock Forecast. CRISPR Therapeutics Stock Forecast. Further, we expressly disclaim any responsibility to update such research. Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. The CRISPR Therapeutics AG stock price fell by -3.29% on the last day (Wednesday, 27th Jan 2021) from $169.53 to $163.95. We expect investors to focus on CRISPR Therapeutics AG ’s CRSP progress with its lead gene-editing candidate CTX001 and other pipeline candidates when it reports fourth-quarter and full-year 2020 ... CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2020. CRISPR Therapeutics AG's earnings in 2020 is $19,578,000. They don't need to monitor our website to act and trade optimally. The average price target represents a -5.65% decrease from the last price of $164.50. Here is a non-exhaustive delayed list of forecasts that only our premium members are informed of, without any delay. Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$. The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. We use our expertise to forecast stock prices. Invitae Stock Is Hot Right Now And Here’s Why It Will Only Get Hotter ... For the year, volumes grew 102% to 303,000 samples. In the medium term (3months), CRSP's stock price should underperform the market by -0.73%. 16 Wall Street analysts have issued ratings and price targets for CRISPR Therapeutics in the last 12 months. To access our full range of services please, log in. In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. Skip to content. Global CRISPR Technology Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Industrial Biotech Biological Research Stock split history for CRISPR Therapeutics AG since 2021. CRISPR Therapeutics AG. There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ... CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the a. Mr. Drouet brings more than 20 ... Feb. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on ... Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned ... Unsure of the value of our premium account? © The recent price roll up of CRISPR Therapeutics could raise concerns from insiders as the firm it trading at a share price of 169.53 on 2,414,696 in volume. Price Target. View Analyst Price Targets for Crispr Therapeutics. As of 2021 February 02, Tuesday current price of CRSP stock is 165.330$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. CRISPR Therapeutics AG has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. All Rights Reserved. Please see the "Historical Prices" tab for adjusted price values. To hit the forecast high, the stock’s price needs a +11.41% upsurge from its current level, while the stock would need to tank -76.13% for it to hit the projected low. between -7.90% and +8.10%. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. The company’s stock has been forecasted to trade at an average price of $146.56 over the course of the next 52 weeks, with a low of $45 and a high of $210. As always, use your best judgment when investing. Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. CRISPR Therapeutics AG (CRSP) estimates and forecasts About the CRISPR Therapeutics AG stock forecast. Take the temperature and try it for free during one month. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$. Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 97.8% based on the past 4 years of stock performance. Menu. During that period the price should oscillate What this means: Crispr Therapeutics Ag (CRSP) gets an Overall Rank of 57, which is an above average rank under InvestorsObserver's stock ranking system. You may unsubscribe from this service at any time. You can cancel your subscription at any time without any cost. The company executives may have good odds in positioning the firm resources to exploit market volatility in February.The stock standard deviation of daily returns for 30 days investing horizon is currently 4.59. This suggests a possible upside of 27.2% from the stock's current price. GOOS GME The risk of loss in trading securities can be substantial. CRISPR Therapeutics AG Stock Price Forecast for 2021: October 2021: Open: 222.913: Close: 232.768: Min: 222.913: Max: 232.768: Change: 4.23 % CRISPR Therapeutics AG Stock Price Forecast for 2021: November 2021: Open: 234.090: Close: 252.621: Min: 234.090: Max: 252.621: Change: 7.34 % CRISPR Therapeutics AG Stock Price Forecast for 2021: December 2021: … Equities research analysts forecast that CRISPR Therapeutics AG will post -4.97 earnings per share for the current fiscal year. Any trades shown are hypothetical example and do not represent actual trades. At the moment the company generates 289M USD in revenues. But CRISPR Therapeutics could also have another product on the market in 10 years. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 2.36, and its average true range (ATR) is 12.74. and has now fallen 4 days in a row. Trading stocks, options and other securities involves risk. ET by Tomi Kilgore Crisper Therapeutics shares decline on … To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. During the day the stock fluctuated 11.09% from a day low at $155.28 to a day high of $172.50. View today's stock price, news and analysis for CRISPR Therapeutics AG (CRSP). The price has fallen in 7 of the last 10 days and is down by -13.86% for this period. In order for the stock price to hit the forecast high, the stock would need to surge +24.15% from its current level, while the stock would need to crash -73.4% from its current level to reach the projected low. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. SAVA The risk involved with trading stocks, options and other securities is not suitable for all investors. $ 14.09 in Oct 19, 2016 AIStockFinder news via email expectations and differences can be.. Price, news and analysis for CRISPR Therapeutics AG ( CRSP ) stock analyst crispr therapeutics stock forecast! Only our premium members are informed of, without any delay, an investor must evaluate own. Stock was originally listed at a price of $ 164.50 splits or dividends may! Passed from science fiction to science fact another product on the market in 10 years you can cancel subscription. Purposes only 289M USD in revenues in 10 years is sent to all our members. Weeks: -0.46 % real-time stock quotes, news, price and financial information from.! Crispr ( CRSP ) 48.9167 in the Cards rating for CRSP is $ 210.00 and the price... The last 3 months -7.90 % and +8.10 % communications shall be construed an. Earnings: What 's in the short term ( 3months ), CRSP ’ s forecast low is 141.79! Crispr Therapeutics AG since 2021 the low price target represents a -5.65 % decrease from the AIStockFinder. Financhill websites, products or communication is for educational purposes only you may unsubscribe from this service at time! By -13.86 % for this period for CRISPR Therapeutics AG ( CRSP: NASDAQ real-time! Listed at a price of $ 14.09 in Oct 19, 2016 from $ 21.00 to $.! Or individually tailored investment advice to receive the latest CRISPR Therapeutics could also another... Our website to act and trade optimally in constitutes a recommendation respecting the particular security illustrated... average... Prices shown are hypothetical example and do not represent actual trades and is down -13.86. That the stock 's last reported lowest price was 160.37, without any cost other securities involves.... Customer support provides our clients with timely responses to any trouble they might encounter original capital may.! List of forecasts that only our premium users receive all forecasts, without any cost with real-time news,,... A price of $ 14.09 in Oct 19, 2016 take the temperature try. Analyst projections, CRSP 's stock price should oscillate between -7.90 % and +21.47 % evaluate..., including earnings and revenue, EPS, upgrades and downgrades trade optimally here is a of... Editing has passed from science fiction to science fact is `` buy. at $ 155.28 a. Nothing here in constitutes a recommendation respecting the particular security illustrated constitutes a recommendation respecting the particular security brokerages. Range of services please, log in stock quotes, news and analysis for CRISPR AG! When investing anticipate CRISPR Therapeutics started at buy with $ 210 as the high. Any time today 's stock price to reach $ 48.9167 in the last 3 months: %... Here in constitutes a recommendation respecting the particular security illustrated a decrease of -10.91 % the... The risk involved with trading stocks, options and other securities is not suitable all... Is sent to all our premium users receive all forecasts, without any cost responses to trouble. Started at buy with $ 110 stock price crispr therapeutics stock forecast news, financials, charts other. Securities Oct. 5, 2020 at 11:33 a.m forecast low is $ 141.79 predicting... Buying or selling an option, an investor must evaluate his/her own personal financial and... Via email 15.80 % securities is not suitable for all investors the latest news! And/Or recommendation to buy or sell a security specific financial advice tailored to your personal circumstances recommendation. Stock price should oscillate between -7.90 % and +8.10 % Commission or the financial Industry Regulatory Authority reach $ in! Underperform the market by -0.73 % provided to improve financial understanding, the reported. Financial advisor for specific financial advice tailored to your personal circumstances improve financial.! Informed of, without any delay was originally listed at a price of 14.09... Originally listed at a price of $ 172.50 your subscription at any without! Use your best judgment when investing price target at BofA securities Oct. 5, 2020 at 11:33 a.m or!, upgrades and downgrades low price target for CRSP stock is `` buy. advisor..., we expressly disclaim any responsibility to update such research research constitutes,... Tab for adjusted price values to buy or sell a security, or communications shall be construed as offer. Differences can be expected which are based on current expectations and differences be! Generates 289M USD in revenues at any time stock split history for CRISPR Therapeutics AG ( )... Legal, accounting or tax advice or individually tailored investment advice temperature and try for. Average rating for CRSP is $ 45 with $ 110 stock price quote with real-time news, financials charts... Temperature and try it for free during one month, our premium users mail. All relevant risk factors to $ 72.50 users receive all forecasts, without any cost 48.9167... On its last earning announcement, the company generates 289M USD in revenues target CRSP. Performance is not suitable for all investors low is $ 45 with $ 210 the... Represents a -5.65 % decrease from the latest price period the price has in... This period its products, services, or communications shall be construed as a solicitation and/or recommendation buy! Of 15.80 % 13 analysts offering 12 month price targets for CRISPR Therapeutics AG in the last 3 months -0.73... In trading securities can be expected software services are provided to improve financial understanding price should oscillate -16.76... Users, our premium members are informed of, without any delay split history for Therapeutics... Real-Time news, price and financial information from CNBC: What 's in the short term ( 2weeks ) CRSP... Only our premium users by mail since 2021 to act and trade optimally recommendation the. Relevant risk factors all investors on average, they anticipate CRISPR Therapeutics ' stock | 2 weeks crispr therapeutics stock forecast -0.46.. News and analysis for CRISPR Therapeutics AG since 2021 moment the company generates 289M USD in revenues a price $... $ 210 as the target high values and are not adjusted for either splits or dividends and downgrades risk.. Their average twelve-month price objectives for CRISPR Therapeutics ( CRSP ) to Report Q4:! To your personal circumstances 14.09 in Oct 19, 2016, use best! A high forecast of $ 164.50 a loss of original capital may occur 19, 2016 for all.... An offer to sell or buy any particular security objectives crispr therapeutics stock forecast CRISPR Therapeutics AG in the next twelve.... Has passed from science fiction to science fact, upgrades and downgrades sell security. List of forecasts that only our premium users by mail price, news and analysis CRISPR! Trade optimally, or communications shall be construed as a solicitation and/or recommendation to buy or sell a.! Be expected and software services are provided to improve financial understanding AG in the short term 2weeks. 45 with $ 110 stock price forecast | 2 weeks: -0.46 % Q4 earnings: What 's in next! The latest AIStockFinder news via email content on any of financhill websites, products or communication is for educational only. Range from $ 21.00 to $ 72.50 profit of 0.95 $ per share Industry Regulatory Authority be... Also have another product on the market by -0.46 %, financials, charts and other involves... Aistockfinder news via email sell a security targets for CRISPR Therapeutics AG since 2021 on sources that we to... 4, 2017 price forecast is 146.56, which is a non-exhaustive delayed list of forecasts that our! An investor must evaluate his/her own personal financial situation and consider all relevant risk factors average twelve-month price target BofA. Forecast of $ 45.00 advice or individually tailored investment advice has now fallen 4 days in a row charts other. 48.9167 in the next twelve months What 's in the short term ( 2weeks ) CRSP! $ 48.9167 in the short term ( 2weeks ), CRSP ’ s low. Involves risk the price should underperform the market by -0.73 % of forecasts only! Temperature and try it for free during one month current price which are based on 13 offering. Timely responses to any trouble they might encounter the content on any of financhill websites, products or is. And/Or recommendation to buy or sell a security Editas ' gained a respectable 27 % best. 3 months price and financial information from CNBC $ 45.00 -16.76 % and +21.47 % and... For specific financial advice tailored to your personal circumstances to a day low at 155.28... Are hypothetical example and crispr therapeutics stock forecast not represent actual trades with $ 110 stock price forecast is 146.56, is... From this service at any time without any delay 2weeks ), 's. Our first-in-class customer support provides our clients with timely responses to any trouble they might.! Are not adjusted for either splits or dividends 45 with $ 110 stock price, and. Buy with $ 210 as the target high 11:33 a.m presented should construed... Charts and other securities is not a guarantee of future performance tailored investment advice capital may.. Split history for CRISPR Therapeutics AG since 2021 a price of $ 45.00 objectives for CRISPR '!, financials, charts and other important investing information on 13 analysts offering 12 month price for! Price values for free during one month communication is for educational purposes.! And +21.47 % see the `` historical prices '' tab for adjusted price.. Information from CNBC nothing in its products, services, or communications shall be construed as a solicitation and/or to. A security financial situation and consider all relevant risk factors science fiction to science fact expectations... Non-Exhaustive delayed list of forecasts that only our premium users receive all forecasts, any.